Table 1 Clinical characteristics of the enrolled patients.

From: Impact of exercise capacity on the long-term incidence of atrial arrhythmias in heart failure

 

All (n = 220)

Lower-risk patients (n = 110)

Higher-risk patients (n = 110)

P value

Median age (IQR), years

67 (59–74)

65 (58–71)

68 (62–76)

0.110

Female sex, N (%)

51 (23)

18 (16)

33 (30)

0.025

Median body mass index (IQR), kg/m2

23.5 (20.8–25.2)

23.4 (20.5–25.2)

23.5 (21.0–25.4)

0.625

Median BNP level (IQR), pg/ml

215.2 (104.1–494.7)

213.9 (103.6–364.8)

217.6 (105.6–618.7)

0.294

Median left ventricular ejection fraction (IQR), %

50 (41–60)

54 (43–61)

49 (40–56)

0.019

Median estimated GFR(IQR), ml/min/1.73 m2

63.0 (52.0–77.8)

65.0 (56.0–75.5)

61.0 (46.0–78.3)

0.141

Peak V̇O2 at 2 months

14.6 ± 3.6

17.4 ± 2.7

11.8 ± 1.8

 < 0.001

Peak V̇O2 at 5 months

16.6 ± 4.7

19.0 ± 4.5

14.2 ± 3.7

 < 0.001

Peak V̇O2 percentage of predicted value

50.3 ± 12.5

57.5 ± 10.7

43.2 ± 9.8

 < 0.001

NYHA class -N. (%)

   

0.066

I

147 (67)

80 (73)

67 (61)

 

II

57 (26)

24 (22)

33 (30)

 

III

16 (7)

6 (6)

10 (9)

 

Coexisting conditions, N (%)

Hypertension

152 (69)

81 (74)

71 (65)

0.189

Diabetes

77 (35)

39(36)

38 (35)

1.000

Atrial fibrillation

24 (11)

7(6)

17(16)

0.050

Prior thromboembolic events

5 (2)

2 (2)

3 (3)

1.000

CHADS2 score (IQR)

2 (2–3)

2 (2–3)

2 (2–3)

0.756

CHA2DS2–VASc (IQR)

4 (3–4)

4 (3–4)

4 (3–5)

0.942

Heart failure with preserved ejection fraction, N (%)

117 (53)

63 (57)

54 (49)

0.280

Cause of heart failure, N (%)

   

0.878

Ischemic

159 (72)

79 (72)

80 (73)

 

Non-ischemic

    

 Idiopathic

31 (14)

17 (16)

14 (13)

 

 Valvular

30 (14)

14 (6)

16 (7)

 

Medications, N (%)

ACE inhibitor or ARB

200 (91)

100 (91)

100 (91)

1.000

Beta-blocker

177 (81)

90 (82)

87 (79)

0.734

Amiodarone

11 (5)

5 (5)

6 (6)

1.000

Preexisting pacemaker or CRT, N (%)

8 (4)

5 (5)

3 (3)

0.486

  1. IQR; interquartile range, GFR; glomerular filtration rate, NYHA; New York Heart Association, ACE; angiotensin-converting enzyme, ARB; angiotensin II receptor blocker, CRT; cardiac resynchronization therapy, BNP; brain natriuretic peptide, GFR; glomerular filtration rate.